Marketing-authorisation holder · United States
Bristol
31 medicines in 2 countries, as authorisation holder.
Loading your page…
Loading your page…
Marketing-authorisation holder · United States
31 medicines in 2 countries, as authorisation holder.
One free account for the Prognia apps: Ward to study, Osler for clinical answers with their sources, and the network to find your colleagues.
Groups are put together by Prognia from the names regulators publish and from company links; they are not an official corporate structure.
Every medicine in the registers under its name, current ones first.
1–25 of 31
| Medicine | Substance | Country | Status | Authorised |
|---|---|---|---|---|
| AUGTYRO160mg | 40mg · Capsule | Repotrectinib | United States | Marketed | 2023 |
| BETAPEN-VK250mg base | 500mg base · Tablet | Phenoxymethylpenicillin | United States | Not marketed | |
| BRISTACYCLINE250mg | 500mg · Capsule | Tetracycline | United States | Not marketed | 1972 |
| BRISTAGEN40mg base/ml · Injectable | Gentamicin | United States | Not marketed | |
| BRISTAMYCIN250mg base · Tablet | Erythromycin | United States | Not marketed | 1974 |
| CAMZYOS10mg | 15mg | 2.5mg | 5mg · Capsule | Mavacamten | United States | Marketed | 2022 |
| ELIQUIS0.15mg · Suspension | Apixaban | United States | Marketed | 2025 |
| ELIQUIS SPRINKLE0.15mg · For suspension | Apixaban | United States | Marketed | 2025 |
| EVOTAZ300mg base; 150mg · Tablet | Atazanavir, Cobicistat | United States | Marketed | 2015 |
| KRAZATI200mg · Tablet | Adagrasib | United States | Marketed | 2022 |
| MEXATE100mg base/vial | 20mg base/vial | 250mg base/vial | 50mg base/vial · Injectable | Methotrexate | United States | Not marketed | 1979 |
| ONUREG200mg | 300mg · Tablet | Azacitidine | United States | Marketed | 2020 |
| POLYCILLIN250mg base | 500mg base · Capsule | Ampicillin | United States | Not marketed | |
| POLYCILLIN100mg base/ml | 125mg base/5ml | 250mg base/5ml | 500mg base/5ml · For suspension | Ampicillin | United States | Not marketed | |
| POLYCILLIN125mg base · Tablet, chewable | Ampicillin | United States | Not marketed | |
| POLYCILLIN-N125MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 1GM BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | 250MG BASE/VIAL **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reason · Injectable | Ampicillin | United States | Not marketed | |
| POLYCILLIN-PRB3.5gm base/bot; 1gm/bot · For suspension | Ampicillin, Probenecid | United States | Not marketed | 1974 |
| POMALYST1mg | 2mg | 3mg | 4mg · Capsule | Pomalidomide | United States | Marketed | 2013 |
| PRECEF10gm/vial | 1gm/vial | 20gm/vial | 2gm/vial | 500mg/vial · Injectable | Ceforanide | United States | Not marketed | 1984 |
| SOTYKTU6MG · Tablet | Deucravacitinib | United States | Marketed | 2022 |
| TETREX100mg hydrochloride | 250mg hydrochloride | 500mg hydrochloride · Capsule | Tetracycline complex | United States | Not marketed | 1957 |
| ULTRACEF500mg base · Capsule | Cefadroxil | United States | Not marketed | |
| ULTRACEF125mg base/5ml | 250mg base/5ml | 500mg base/5ml · For suspension | Cefadroxil | United States | Not marketed | |
| VERSAPEN112.5mg ampicil/5ml | 112.5mg ampicil/ml | 225mg ampicil/5ml · For suspension | Hetacillin | United States | Not marketed | |
| VERSAPEN-K225mg ampicil | 450mg ampicil · Capsule | Hetacillin | United States | Not marketed | 1971 |
Where it holds or makes medicines, with how many are current.
| Country | Medicines | Current | Past | Companies |
|---|---|---|---|---|
| United States | 29 | 29 | 0 | CompaniesAll medicines |
| Romania | 2 | 0 | 2 | CompaniesAll medicines |
The ATC groups most of its medicines belong to, largest first.
The active substances in most of its medicines.
Compiled by Prognia from the public medicine and company registers below. Logos are not used.
Source: U.S. FDA, Drugs@FDA / openFDA. FDA does not endorse this site.
Licence: Public domain (U.S. Government work)
Report an error or request removalCorrections from the company itself are welcome.
Other companies in the same group.
Ranked by their number of medicines.